Research programme: peptide-based therapeutics - Longevity Biotech

Drug Profile

Research programme: peptide-based therapeutics - Longevity Biotech

Alternative Names: 5A apoA-I mimetic peptide; LBT 3627; LBT-6030

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Longevity Biotech
  • Developer Longevity Biotech; University of Nebraska Medical Center
  • Class Neuroprotectants; Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Vasoactive intestinal polypeptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Type 2 diabetes mellitus
  • Research Asthma

Most Recent Events

  • 02 Jan 2018 Longevity receives SBIR grant from the the National Heart, Lung, and Blood Institute for 5A apoA-I mimetic peptide development in Asthma
  • 02 Jan 2018 Early research in Asthma in USA (Inhalation)
  • 02 Jan 2018 Longevity announces intention to submit IND to US FDA for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top